Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

75%(3 trials)

Phase Distribution

Ph not_applicable

20%

Ph phase_1

20%

Ph phase_4

20%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

2(40.0%)

Phase 4Post-market surveillance

1(20.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Other(1)

Detailed Status

Completed4

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (20.0%)

Phase 22 (40.0%)

Phase 41 (20.0%)

N/A1 (20.0%)

Trials by Status

unknown120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

unknownphase_2

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

NCT00943917

completednot_applicable

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

NCT01147627

Clinical Trials (5)

Showing 5 of 5 trials

NCT03287076Phase 2

Trial of EXenatide in Acute Ischaemic Stroke

Unknown

NCT03167411Phase 1

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Completed

NCT03160261Phase 4

Effect of Exenatide on Cortisol Secretion

Completed

NCT00943917Phase 2

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

Completed

NCT01147627Not Applicable

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5